Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Be prepared.

<< Previous

Bullboard Posts

Next >>

Comment by IrishCanuckon Aug 26, 2021 7:30am

232 Views

Post# 33766257

RE:Be prepared.

"I better say a lot of prices because if I hit one I can seem prophetic"

Rarbar99 wrote:

Although I'm bullish on this company in the long run. Expect a drop to 0.80-0.90 as early as next month. And a possible crash down to 0.60 depending on how October's report will go.

It is what it is, these numbers are all very real possibilities. DCA if you're bullish but please don't think for a second that we've bottomed out. We can still drop another 50% from here.

<< Previous

Bullboard Posts

Next >>

The top TSX healthcare stocks under $1